Contraception Update 2019

September 10th 2019

Minnesota Reproductive and Sexual Health Update

Patty Cason, MS, FNP-BC

envisionsrh.com

This presentation includes discussion of use of products "off-label".

When the speaker mentions use of medications for purposes other than what is included in their FDA label they will be identified as such.

Objectives

- Describe two innovations in contraception
- Discuss extended use of implants and IUDs
- Demonstrate use of patient-centered questions to assist patients with contraceptive decision making

Outline

- Update on best practices
- New contraceptive products on the market
- Contraceptive products in development







U.S. Medical Eligibility for Contraceptive Use

U.S. Selected Practice Recommendations

Providing Quality Family Planning Services: Recommendations of the CDC and U.S. OPA


UTILIZE NATIONAL GUIDELINES




Find the APP

- ✓ Play store on android
- ✓ App store on iPhone
 - ✓ Go to search field
 - ✓ Type in: Contraception CDC





US Medical Eligibility Criteria: Categories



U.S. Selected Practice Recommendations

Provides recommendations on optimal use of contraceptive methods for persons of all ages, including adolescents.



Ask About Reproductive Goals PATH

PA: Parenting/Pregnancy Attitudes:

Do you think you might like to have (more) children at some point?

T: Timing: When do you think that might be?

H: How Important: How important is it to you

to prevent pregnancy (until then)?

(Hatcher, R.A, et, al. 2018. Geist, C., et, al. 2019. Callegari, Aiken et al. 2017)

Reproductive Intention/Goals

Clarifies motivation and degree of acceptability regarding pregnancy

...so we can offer appropriate interventions

+/Contraception

+/Preconception
Care

Infertility
Services or
Adoption

"Do you have a sense of what is important to you in your birth control method?"

Best Question




Use Visual Aids & Tactile Aids

HOW WELL DOES BIRTH CONTROL WORK?

What is your chance of getting pregnant?




















This work by the UCSF School of Medicine Bixby Center and Bedsider is licensed as a Creative Commons Attribution - NonCommercial - NoDeriv 3.0 Unported License. Updated January 2016. FYI, without birth control, over 90 in 100 young women get pregnant in a year.








Tactile Aids






























BEDSIDER--Patient Education Resource



Http://bedsider.org/

- "User friendly", accurate information on all contraceptive methods
- Will set up reminders for contraception adherence and appointments
- Patient testimonials
- Free provider resources



Bedsider.org is ALSO a Provider Resource

Http://bedsider.org/

Find:

- How to prevent a vasovagal
- A patient testimonial about vasectomy
- Posters for the office

Prevent Vasovagal Reactions



Pre-syncopal Signs + Symptoms

- Facial pallor (distinct green hue)
- Diaphoresis, feeling warm or cold
- Sudden need to go to the bathroom
- Nausea
- Yawning
- Pupillary dilatation
- Weakness, light-headedness
- Visual blurring/ tunnel vision



STOP Vasovagal Syncope

- Isometric contractions of the extremities
- Intense gripping of the arm, hand, leg and foot muscles
- No need to bring the legs together or change position just tense the muscles



Vasovagal Prevention

- Anticipatory guidance!
- Good hydration
- Eat before placement
- Prophylactically contract muscles if known history



Non-delayed Contraception



- Quick start all methods
- Same day placement of implant, and IUDs
 - —the patient wants it placed that day
 - -no contraindications

Dispense More Pills, Patches, & Rings

Provision of 13 cycles

- Halves pregnancy and abortion rates
- Improves continuation of use
- Decreases coverage gaps

Offer Continuous Use Combined Hormonal Contraceptives

- Delays or eliminates bleeding
- More effective; less ovarian activity
- More margin for user error
- Demonstrated safety
- Less PMS/PMDD
- Rx extended-use brand




Or just skip hormone-free interval



Continuous Use Combined Oral Contraceptives

Monophasic

21 days



Or 24 days





 Continuous use means NO PLACEBO, no hormone-free interval (HFI)

Continuous Use Vaginal Ring


- Goal is no bleeding
- Ring left in place in vagina for 1 month
- First day of each calendar month switch ring!
- Each ring has enough hormone to last at least 6 weeks
- 4 day HFI when needed

Depo Medroxyprogesterone Acetate (DMPA, "the shot", Depo-Provera)



DMPA Where, When, & How?

- Effective through 15 weeks
- Use a long enough needle
- Do not massage after injection
- DMPA SQ 104 mg/0.65mL



DMPA & Fracture Risk

- DMPA use was associated with slightly increased fracture risk compared with other methods
- The absolute risk of fracture was small
- No increased risk of fracture was observed after discontinuation
- Use of DMPA beyond 2 years should not be considered an absolute contraindication

DMPA and Weight Gain

 DMPA users who gain ≥ 5% of their baseline weight within 6 months are predicted to continue gaining... and gaining

 We can use this information to counsel those at risk of excessive weight gain

(Bonny, Secic et al. 2011; dos Santos Pde, Modesto et al. 2014; Le, Rahman et al. 2009; Lopez, Ramesh et al. 2016; Pantoja, Medeiros et al. 2010; Risser, Gedter et al. 1999)

DMPA and Metabolism

- Changes occur in carbohydrate metabolism in DMPA users
- Decrease in lean body mass
- Increase in % body fat
- Data show regular aerobic exercise may exert a protective effect

DMPA Return to Fertility Precaution

- May not return to ovulation, menstruation or fertility for > 1 year
- Delay in return to fertility can occur regardless of the length of use

IN CASE OF ENERGENCY



Tiers of Emergency Contraceptive (EC) Effectiveness

1. Top tier: Copper IUD (Paragard)




- 2. Second tier: Ulipristal acetate (UPA) (ella)
- 3. Third tier: Levonorgestrel (LNG) (Plan B)

- Effectiveness of oral EC decreases with increasing weight
- Majority of pregnancies occur subsequent
 to EC use due to continued unprotected sex

Quickstarting Hormonal Contraception After UPA

"After using ella, if a woman wishes to use hormonal contraception, she should do so no sooner than 5 days after the intake of ella, and she should use a reliable barrier method until the next menstrual period."



Shen J, et, al. 2019 Glasier A, et al. 2011. Rapkin RB, et, al. 2011.


Cu IUD for EC

- Failure rate ZERO-0.09%.
- Provides ongoing contraception
- High continuation rates
- New data showing no
 pregnancies when placed 6 14 days after unprotected sex with a negative pregnancy test





Thompson, I. et, al. 2019 Cleland K et al. 2012 Wu S, et al. 2010 Turok et al. 2013.



REMOVAL

Expectation Among Providers About Duration Of Use

Unlike with other reversible contraceptives

- high up-front cost,
- the focus on continuation rates in some studies
- the fact that most common side effects are short lived
- the name "long-acting" reversible contraception

If you would like it out for any reason...

Reframe the concept of "early" removal

No particular duration of use of an implant or an IUD is expected

Language for LARC

"This method is good for **up to** ____ years but if you want to get pregnant before then or you would like it out for any reason, come in, we will remove it and your ability to get pregnant will go back to whatever is normal for you immediately."



TOP TIER



Nexplanon[®] Procedure-related Events 7364 procedures

- Incorrect placement 1%
- Pins and needles/numbness in the arm/hand/fingers was the most common patient-reported event
- The most common challenge reported by HCPs during placement was removal of the end cap


Nexplanon[®] Procedure-related Events 7364 procedures

- No implants were localized outside the arm
- The most common challenge reported by HCPs during removal was fibrotic tissue

Migration of Implant 1.3 Migrations per Million Placements

N=38 cases of migration:

- lung/pulmonary artery (n=9)
- chest wall (n=1)
- vasculature at locations other than the lung/pulmonary artery (n=14)
- extravascular migrations (n=14) to other body sites (e.g., the axilla and clavicle/neck line/shoulder)



New Location and Arm Position

- No major neurovascular structures were identified overlying the triceps:
 - —8—10 cm proximal to the medial epicondyle
 - -and 3-5 cm posterior to the sulcus
- Elbow flexion deflects the ulnar nerve away from this area and may further decrease risk of injury

to avoid placement in the biceps groove, no matter how superficial that placement might be

Place over the triceps

(Rowland, Mansour et al. 2017)

Is the Implant Effective in Obese People?

Package insert states:

"No Studies in women >130% of their ideal body weight"

Highly effective, including among people with high BMI

Lazorwitz, A. et. Al. 2019 Lopez, Bernholc et al. 2016; Mornar, Chan et al. 2012; Morrell, Cremers et al. 2016; Xu, Wade et al. 2012

Menstrual Effects: Cu IUD

NSAIDs prophylactically with food

- Pre-emptive use for first 3 cycles
- Start before onset of menses-- antiprostaglandin effect
 - –Naproxen sodium 220mg x2 BID (max 1100mg/day)
 - -Ibuprofen 600-800mg TID (max 2400mg/day)



Comparing bleeding patterns for the levonorgestrel (LNG) 52 mg, 19.5 mg, and 13.5 mg intrauterine systems (IUS)

Amenorrhea after the first 6 months:

- LNG 52mg (11%)
- LNG 19.5mg (5%)
- LNG 13.5mg (3%)

Bleeding patterns for the LNG 52 mg, LNG 19.5 mg, and LNG 13.5 mg IUS

Infrequent bleeding (after 1 year):

- LNG 52 mg (31%)
- LNG 19.5 mg (26%)
- LNG 13.5 mg (20%)

Irregular Bleeding After 90 days

- LNG 52 mg (6%)
- LNG 19.5 mg (17%)
- LNG 13.5 mg (23%)

Frequent & Prolonged Bleeding

- Similar over 2 years for all products
- LNG 13.5 mg more frequent or prolonged bleeding than LNG 19.5 mg and LNG 52 mg

Conclusions

- 52 mg LNG IUS has more amenorrhea and infrequent bleeding than lower doses
- Users of 52 mg LNG IUS have less irregular bleeding than people using IUSs with lower doses



Implant

LNG 52 IUD

EXTENDED USE

Etonogestrel implant



- The EPIC Study-- part of Contraceptive Choice project, 291 women provided 444 user-years of extended use. No pregnancies.
- 7-country study, 390 used implant beyond 3 years more than 200 of them used for at least 5 years. No pregnancies.

Threshold For Ovulation Suppression >90 pg/mL

Serum ENG median levels remained above 90 pg/mL for women of all BMIs





>90 pg/mL



- The absolute threshold of contraceptive effectiveness remains poorly defined
- The threshold of effectiveness may be <90 pg/mL because cervical mucus changes may prevent pregnancy should ovulation occur

Levonorgestrel-releasing Intrauterine System 52 Mg



7 Year Data




- Approved for up to 5 years
- Data show that it is highly effective for at least 2 additional years of use
- 6th year failure rate 0.25
- 7th year failure rate 0.43 (n=496)
- Another trial showed 7-year pregnancy cumulative failure rate 0.5 (n=398)

52-mg LNG-IUD Data Suggest

- Efficacy as long as 15 years
- HCPs & policy makers could take advantage of the present information to decide to maintain the same device at least up to seven years
- Furthermore, amenorrhea could be a good indicator of contraceptive effect

Liletta* Levonorgestrel-releasing Intrauterine System 52 Mg



*The 340B price for Liletta is \$50

LNG 52 LILETTA

- FDA approved use up to 5 years
- Submitted to FDA for 6 year indication
- The clinical trial is ongoing to 10 years
- LNG content at 5 year supports
 equivalence to Mirena and efficacy to at
 least 7 years



Second Tier













The Pill

The Patch

The Ring

The Shot


Every, Single, Day,

Every week

Every month

Every 3 months

Annovera Contraceptive Vaginal Ring (CVR)



One-Year Vaginal Contraceptive Ring

- Segesterone acetate (Nestorone®) + ethinyl estradiol
- Developed by the Population Council
- Two phase 3 open-label safety & efficacy trials

One-Year Vaginal Contraceptive Ring

- Commercially available Fall 2019! NOW
- Participants ranked high in convenience, ease of use, and satisfaction
- Side effect & bleeding profile similar to NuvaRing
- Does not require refrigeration



Use of the Annovera CVR

- In for 21 days, then removed for 7 days to induce a scheduled bleed (like a menses)
- Can remove for up to 2 hours for intercourse or cleaning
- Can use water-based creams and lubricants
- Can not use oil and silicone-based lubricants as they alter exposure to EE and segesterone acetate

Annovera CVR

- TherapeuticsMD has agreed to provide significantly reduced pricing to Title X family planning clinics
- Not in same FDA contraceptive category as NuvaRing, so must be covered under no cost-sharing rules of ACA

Comparison

	NuvaRing	Annovera
Lifespan	6 weeks	1 year (13 cycles)
Progestin release rate	Etonogestrel 120 mcg/day	Nestorone 150 mcg/day
Ethinyl estradiol release rate	15 mcg/day	13 mcg/day
Diameter	54 mm	56 mm
Thickness	4 mm	8.4 mm



Drospirenone (DRSP) 4 mg Progestin-only Pill (POP) Slynd™

- DRSP is progestin in: Yaz, Yazmin, Ocella
- 24/4 Dosing Regimen
 - -24-hour missed pill window
- No estrogen to increase thromboembolic risk
- Commercially available early Fall 2019! NOW

DRSP 4 mg

- Perfect use Pearl index (based on 14,329 cycles) of 0.73 which is equivalent to currently available combined hormonal pills
- No case of deep vein thrombosis or pulmonary embolism

DRSP 4 mg

Laboratory parameters, weight, heart rate, and blood pressure showed no statistically significant changes due to the treatment


DRSP 4 mg

- Diuretic effect like spironolactone; may help PMDD, PCOS, hirsuitism
- One case of hyperkalemia
- Slynd™ is contraindicated in people with conditions that predispose to hyperkalemia (e.g. renal impairment, hepatic impairment and adrenal insufficiency)

K+

Check serum potassium levels during the first treatment cycle in those receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentrations.

Best News



Because DRSP Has a Long Half Life

- 30-33 hour half life
- The other currently available POP contains northindrone which has a 8-9 hour half life!

Third Tier





https://www.myonecondoms.com/

- 10 lengths. 9 widths. 60 sizes.
- Standard condoms can sometimes feel too tight, too loose, too short, too long. Sound familiar? That's because most condoms were the same size. Until now.
- You wouldn't settle for one-size-fits-all pants or shoes. Penises come in many different sizes. Isn't it about time condoms did, too?
- Find a condom that's perfectly fit for you.

Female Condom FC2



Internal Condom

- Comes with silicone-based lubricant on the inside
- Additional lubrication can be used
- Does not have to be water soluble
- Does not contain spermicide
- STI protection that doesn't rely on a partner maintaining an erection

Internal

- Helps to prevent pregnancy, STIs & HIV
- Can be used during anal sex (remove the inner ring)
- Now available with a prescription for no cost

Uninsured or Underinsured


- Patient Assistance Program
 - -12-Pack for \$28.95
 - -24-Pack for \$47.95
- 340B Prime Vendor Program (PVP)
 - -12-Packs of FC2

Fertility Awareness Based Methods (FABMs)

Intro to FABMs in NCTCFP webinar:

https://bit.ly/2LVnrb3

Two General Categories of Apps





Digital Platforms For Existing FABMs

Algorithms


Algorithms





Dot algorithm coming soon

Natural Cycles






CONTRACEPTIVE METHODS IN DEVELOPMENT

VeraCept In Phase 3

- 175 mm² of copper
 - Near cervix and cornua
- Nitinol frame
 - -Shape memory allows pre-loading
 - -Small diameter inserter (3.7mm)
 - –Compliant arms
 - —Fundus seeking
- Pre-cut strings


VeraCept Intrauterine Copper Contraceptive



IUB™

- Spherical intrauterine platform
- Nitinol frame; a biocompatible nickeltitanium alloy (used in vascular stents and Essure)
 - —The IUB™ adapts to the uterine cavity
- 3 sizes ranging from 12 mm to 18 mm in diameter
- Out of 49 placements 9 expulsions

IUB^{TM}



Head to Head Comparison with Paragard

- Mona Lisa® NT Cu380 Mini
 - -Copper surface of 380 mm²
 - -24 mm wide X 30 mm long
- Based on the Nova T 380
- Polyethylene frame with barium sulfate

Mona Lisa® NT Cu380 Mini



LevoCept Phase 2


- LNG 52mg on a nitinol frame (like VeraCept)
- Primary outcome measure is effectiveness
- Other outcome measures include
 - –Ease of placement
 - -Placement success
 - –Safety
 - —Tolerability
- Discontinuation rate and reasons
- Estimated Study Completion Date: 7/20


Amphora®


- Spermicidal contraceptive
- Does not contain nonoxynol 9
- Phase 3 study underway
- Data expected Q1 2019
- Already licensed as a lubricant
- Potential additional indications: prevention of chlamydia, gonorrhea and recurrent bacterial vaginosis



Pilot study on functional performance and acceptability of two new synthetic adhesive male condoms (Wondaleaf): a randomized crossover trial







a) The layout of Wondaleaf-On-Man and

its smaller version, Wondaleaf-Cap. The thickness of both condoms is 0.02mm.



c) Wondaleaf-Cap duly deployed on the penis. The loose-fitting condom (A) covers the glans penis, while the adhesive shield sticks onto the penile shaft (B) and onto itself (C) to form the proximal part of the condom (B) and two lateral tabs (C) respectively. The tabs that protrude laterally are soft and thin.



d) Durex-Together expanded and laid flat. It has nominal width 52.5mm, length 190mm, and thickness 0.07mm. It is prelubricated, and features an easy-on shape.



Ting, C. Y., et. Al, 2019 Copyright © 2019 Elsevier Inc.